PubMed:17854040 / 1699-2056 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"4370","span":{"begin":108,"end":111},"obj":"OrganismTaxon"},{"id":"4371","span":{"begin":135,"end":145},"obj":"ChemicalEntity"},{"id":"4372","span":{"begin":328,"end":347},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A39","pred":"db_id","subj":"4370","obj":"NCBITaxon:10407"},{"id":"A40","pred":"db_id","subj":"4371","obj":"MESH:D019259"},{"id":"A41","pred":"db_id","subj":"4372","obj":"MESH:D006509"},{"id":"A42","pred":"db_id","subj":"4372","obj":"MESH:D015658"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients."}

{"project":"LitCoin-sentences","denotations":[{"id":"T12","span":{"begin":0,"end":357},"obj":"Sentence"}],"text":"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients."}

{"project":"LitCoin-entities-OrganismTaxon-PD","denotations":[{"id":"T57","span":{"begin":108,"end":111},"obj":"OrganismTaxon"},{"id":"T58","span":{"begin":328,"end":331},"obj":"OrganismTaxon"},{"id":"T59","span":{"begin":332,"end":335},"obj":"OrganismTaxon"}],"attributes":[{"id":"A57","pred":"db_id","subj":"T57","obj":"NCBItxid:10407"},{"id":"A58","pred":"db_id","subj":"T58","obj":"NCBItxid:10407"},{"id":"A59","pred":"db_id","subj":"T59","obj":"NCBItxid:57667"},{"id":"A60","pred":"db_id","subj":"T59","obj":"NCBItxid:35274"},{"id":"A61","pred":"db_id","subj":"T59","obj":"NCBItxid:12721"},{"id":"A62","pred":"db_id","subj":"T59","obj":"NCBItxid:11709"},{"id":"A63","pred":"db_id","subj":"T59","obj":"NCBItxid:11676"}],"text":"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients."}

{"project":"LitCoin_Mondo","denotations":[{"id":"T12","span":{"begin":336,"end":347},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A12","pred":"mondo_id","subj":"T12","obj":"0100128"}],"text":"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T26","span":{"begin":58,"end":67},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":157,"end":163},"obj":"GeneOrGeneProduct"},{"id":"T28","span":{"begin":164,"end":170},"obj":"GeneOrGeneProduct"},{"id":"T29","span":{"begin":269,"end":275},"obj":"GeneOrGeneProduct"}],"text":"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T14","span":{"begin":95,"end":104},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T15","span":{"begin":122,"end":129},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T16","span":{"begin":332,"end":347},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A14","pred":"originalLabel","subj":"T14","obj":"D004630"},{"id":"A15","pred":"originalLabel","subj":"T15","obj":"D013180"},{"id":"A16","pred":"originalLabel","subj":"T16","obj":"D015658"}],"text":"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T17","span":{"begin":122,"end":129},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T18","span":{"begin":332,"end":335},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A17","pred":"ID:","subj":"T17","obj":"D013180"},{"id":"A18","pred":"ID:","subj":"T18","obj":"DISEASE"}],"text":"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T23","span":{"begin":135,"end":145},"obj":"ChemicalEntity"}],"attributes":[{"id":"A23","pred":"ID:","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_63577"}],"text":"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T40","span":{"begin":108,"end":111},"obj":"OrganismTaxon"},{"id":"T41","span":{"begin":328,"end":331},"obj":"OrganismTaxon"},{"id":"T42","span":{"begin":332,"end":335},"obj":"OrganismTaxon"},{"id":"T43","span":{"begin":348,"end":356},"obj":"OrganismTaxon"}],"text":"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T23","span":{"begin":135,"end":145},"obj":"ChemicalEntity"},{"id":"T43","span":{"begin":348,"end":356},"obj":"OrganismTaxon"},{"id":"T42","span":{"begin":332,"end":335},"obj":"OrganismTaxon"},{"id":"T41","span":{"begin":328,"end":331},"obj":"OrganismTaxon"},{"id":"T40","span":{"begin":108,"end":111},"obj":"OrganismTaxon"}],"attributes":[{"id":"A23","pred":"ID:","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_63577"}],"text":"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients."}